Evidence map›Paper›PMID 11885979›Full record

ArticleJournal of biomolecular NMR2002

Solution structure of N-terminal SH3 domain of Vav and the recognition site for Grb2 C-terminal SH3 domain.

Kenji Ogura, Koji Nagata, Masataka Horiuchi, Etsuko Ebisui, Tomoyo Hasuda, Satoru Yuzawa, Motohiko Nishida, Hideki Hatanaka, Fuyuhiko Inagaki

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biomolecular NMR, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kenji OguraGraduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Koji Nagata
Masataka Horiuchi
Etsuko Ebisui
Tomoyo Hasuda
Satoru Yuzawa
Motohiko Nishida
Hideki Hatanaka
Fuyuhiko Inagaki
Hokkaido University · JPTokyo Metropolitan Institute of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The three-dimensional structure of the N-terminal SH3 domain (residues 583-660) of murine Vav, which contains a tetra-proline sequence (Pro 607-Pro 610), was determined by NMR. The solution structure of the SH3 domain shows a typical SH3 fold, but it exists in two conformations due to cis-trans isomerization at the Gly614-Pro615 bond. The NMR structure of the P615G mutant, where Pro615 is replaced by glycine, reveals that the tetra-proline region is inserted into the RT-loop and binds to its own SH3 structure. The C-terminal SH3 domain of Grb2 specifically binds to the trans form of the N-terminal SH3 domain of Vav. The surface of Vav N-terminal SH3 which binds to Grb2 C-terminal SH3 was elucidated by chemical shift mapping experiments using NMR. The surface does not involve the tetra-proline region but involves the region comprising the n-src loop, the N-terminal and the C-terminal regions. This surface is located opposite to the tetra-proline containing region, consistent with that of our previous mutagenesis studies.

Indexed as

Adaptor Proteins, Signal TransducingCell Cycle ProteinsAmino Acid SequenceAnimalsBinding SitesGRB2 Adaptor ProteinIsomerismMiceMolecular Sequence DataMutagenesis, Site-DirectedNuclear Magnetic Resonance, BiomolecularProtein BindingProtein ConformationProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-vavAdaptor Proteins, Signal TransducingCell Cycle ProteinsGRB2 Adaptor ProteinGrb2 protein, mouseProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-vavSolutionsVav1 protein, mouse

Identifiers

PMID11885979
OpenAlexW12002884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.